CN114224935A - Cold compress spray for relieving gout and preparation method thereof - Google Patents
Cold compress spray for relieving gout and preparation method thereof Download PDFInfo
- Publication number
- CN114224935A CN114224935A CN202111664767.0A CN202111664767A CN114224935A CN 114224935 A CN114224935 A CN 114224935A CN 202111664767 A CN202111664767 A CN 202111664767A CN 114224935 A CN114224935 A CN 114224935A
- Authority
- CN
- China
- Prior art keywords
- spray
- cold compress
- water
- relieving gout
- gout
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007921 spray Substances 0.000 title claims abstract description 45
- 201000005569 Gout Diseases 0.000 title claims abstract description 23
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 50
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 23
- 238000001914 filtration Methods 0.000 claims description 19
- 240000007817 Olea europaea Species 0.000 claims description 18
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims description 14
- 238000011049 filling Methods 0.000 claims description 14
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 14
- 238000003756 stirring Methods 0.000 claims description 14
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 claims description 13
- 235000013923 monosodium glutamate Nutrition 0.000 claims description 13
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 12
- 239000004223 monosodium glutamate Substances 0.000 claims description 11
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 11
- 241000208688 Eucommia Species 0.000 claims description 10
- 239000000706 filtrate Substances 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- 238000010438 heat treatment Methods 0.000 claims description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-N sodium;hydron;carbonate Chemical compound [Na+].OC(O)=O UIIMBOGNXHQVGW-UHFFFAOYSA-N 0.000 claims description 6
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 13
- 229940079593 drug Drugs 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 7
- 206010018634 Gouty Arthritis Diseases 0.000 abstract description 4
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 208000002193 Pain Diseases 0.000 abstract description 3
- 230000036407 pain Effects 0.000 abstract description 3
- 206010067484 Adverse reaction Diseases 0.000 abstract description 2
- 230000006838 adverse reaction Effects 0.000 abstract description 2
- 230000017531 blood circulation Effects 0.000 abstract description 2
- 230000035699 permeability Effects 0.000 abstract description 2
- 238000002474 experimental method Methods 0.000 description 13
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 9
- 208000000114 Pain Threshold Diseases 0.000 description 7
- 230000037040 pain threshold Effects 0.000 description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 210000000544 articulatio talocruralis Anatomy 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 238000009835 boiling Methods 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 229940126673 western medicines Drugs 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 3
- 210000001503 joint Anatomy 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229940116269 uric acid Drugs 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 201000001431 Hyperuricemia Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000011194 food seasoning agent Nutrition 0.000 description 2
- 229910017053 inorganic salt Inorganic materials 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 229940073490 sodium glutamate Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- TWFZGCMQGLPBSX-UHFFFAOYSA-N Carbendazim Natural products C1=CC=C2NC(NC(=O)OC)=NC2=C1 TWFZGCMQGLPBSX-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 206010023203 Joint destruction Diseases 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010029174 Nerve compression Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- JNPZQRQPIHJYNM-UHFFFAOYSA-N carbendazim Chemical compound C1=C[CH]C2=NC(NC(=O)OC)=NC2=C1 JNPZQRQPIHJYNM-UHFFFAOYSA-N 0.000 description 1
- 239000006013 carbendazim Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000000674 effect on sodium Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/46—Eucommiaceae (Eucommia family), e.g. hardy rubber tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dispersion Chemistry (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the technical field of medicines, and particularly relates to a cold compress spray for relieving gout and a preparation method thereof; the cold compress spray for relieving gout comprises: the cold compress spray is an external medicine, adverse reaction and toxic and side effects are remarkably reduced, and the cold compress spray has good permeability, can immediately decompose the tophus after being quickly kneaded and absorbed by hands, promotes blood circulation, quickly relieves pain, has obvious treatment effect, remarkably improves the medication compliance of patients with gouty arthritis, and improves the life quality of the patients.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to a cold compress spray for relieving gout and a preparation method thereof.
Background
Gout is directly related to hyperuricemia caused by purine metabolic disorder and/or reduction of uric acid excretion, and belongs to the category of metabolic rheumatism. Gout can be complicated with kidney disease, and severe cases can cause joint destruction and renal function damage, often accompanied with hyperlipidemia, hypertension, diabetes, arteriosclerosis, coronary heart disease, etc. Hyperuricemia is the basis for the development of gout.
Gout belongs to the categories of arthralgia syndrome, gout, historical segment and the like in traditional Chinese medicine, and refers to symptoms of arthralgia, myalgia, numbness, heaviness and unsmooth flexion and extension caused by exogenous pathogenic factors blocking channels and collaterals, stagnation of qi and blood and deficiency of liver and kidney. Gout patients often develop tophi. Seen subcutaneously around the pinna, around the joints, tendons, soft tissues, etc. of the patient. Tophus formed on various parts of the body, especially four limbs, not only seriously affects the appearance of the limbs, but also leads to joint deformity, dysfunction, nerve compression, skin ulceration and prolonged unhealed sinus, and needs to be treated by operation.
At present, colchicine is used as a treatment medicament for gouty arthritis, and Baotan or indomethacin can be selected. The continuous rise of serum uric acid can also be treated by using the carbendazim, and the medicine plays a role in treating the reabsorption of urate by inhibiting renal tubules and is one of effective treatment medicines. If kidney disease is present, allopurines are often the treatment of choice. In the acute stage, steroid injection into joints, joint immobilization and cold compress of local parts can obviously relieve symptoms. However, although the western medicines can rapidly relieve symptoms, the recurrence rate is high, and the disease can rebound after the medicine is stopped, the western medicines must be taken for a long time without interruption, so that the western medicines bring a large economic burden to patients, and the western medicines have large toxic and side effects on the kidney after long-term administration. Therefore, the development of a spray for effectively treating gouty arthritis is a problem which needs to be solved at present.
Disclosure of Invention
The invention aims to provide a cold compress spray for relieving gout, which has the advantages of quick response, short treatment course, low toxic and side effects, simple preparation process and convenient use.
Specifically, the present invention provides:
a cold compress spray for relieving gout comprises: alkaline ionized water, sodium bicarbonate, L-carnitine, eucommia bark water extract, green olive juice and monosodium glutamate.
The cold compress spray for relieving gout comprises the following components in parts by weight:
the pH value of the alkaline ionized water is 10.0-10.9.
A preparation method of a cold compress spray for relieving gout comprises the following steps:
step 1, adding baking soda into alkaline ionized water, and after uniformly stirring, enabling the pH value to reach 12-13;
step 2, adding L-carnitine into the soda alkaline water obtained in the step 1, uniformly stirring, and standing;
step 3, adding the green olive juice of the eucommia bark water extract into the solution obtained in the step 2, and filtering;
step 4, heating the filtrate obtained in the step 3, adding monosodium glutamate, standing and filtering;
and 5, concentrating the liquid obtained in the step 4 to a relative density of 1.10-1.15 at 25 ℃, and filling the spray into a filling machine to obtain the cold compress spray.
The alkaline ionized water of the present invention is water that is directly collected or produced by an alkaline ion water treatment apparatus (also referred to as an alkaline ionizer) and exhibits alkalinity, and is also referred to as electrolyzed water. The alkaline ionized water is purchased from the Kyoto Shanghai city, and the brand is imported table salt ocean alkaline ionized water.
Preparing a eucommia bark water extract: pulverizing cortex Eucommiae, sieving with 60 mesh sieve, weighing 40g powder, boiling in 1000mL sterile distilled water for 4h, filtering with 300 mesh sieve, collecting filtrate, concentrating in water bath, evaporating to obtain dry liquid, and adding distilled water to obtain cortex Eucommiae water extract with concentration of 3 g/L.
Preparation of green olive juice: putting the cleaned green olive into boiling water, adding 0.1% citric acid solution, scalding for 5min, taking out, washing in flowing water to remove surface wax, softening pulp tissue, and protecting color; extracting the pitted olive pulp in a material-water ratio of 1:5(g/mL) for 2h at 50 ℃ and 400r/min in a temperature-controlled stirrer; filtering the extracted olive juice with gauze to obtain clear and transparent green olive juice.
The baking soda and the sodium bicarbonate have the molecular formulaNaHCO3Is an inorganic salt. Purchased from the market.
The L-carnitine, also called L-carnitine and vitamin BT, has a chemical formula of C7H15NO3Purchased from the market.
The monosodium glutamate is sodium glutamate, is a delicate flavor seasoning, and is easily soluble in water; purchased from the market.
Compared with the prior art, the invention has the following advantages and positive effects:
1. the spray is an external medicine, adverse reactions and toxic and side effects are remarkably reduced, the permeability of the spray is good, and after the spray is quickly kneaded and absorbed by hands, the tophus can be immediately decomposed to promote blood circulation, so that pains are quickly relieved, the treatment effect is obvious, the medication compliance of patients with gouty arthritis is remarkably improved, and the life quality of the patients is improved;
2. the invention has scientific compatibility, has the advantages of quick response, short treatment course, low cost and the like, and has simple and convenient preparation process, stable and safe drug effect, stable preparation system, long-term storage, convenient use and easy popularization and application.
Detailed Description
The present invention is further described in the following description of the specific embodiments, which is not intended to limit the invention, but various modifications and improvements can be made by those skilled in the art according to the basic idea of the invention, within the scope of the invention, as long as they do not depart from the basic idea of the invention.
Preparing a eucommia bark water extract: pulverizing cortex Eucommiae, sieving with 60 mesh sieve, weighing 40g powder, boiling in 1000mL sterile distilled water for 4h, filtering with 300 mesh sieve, collecting filtrate, concentrating in water bath, evaporating to obtain dry liquid, and adding distilled water to obtain cortex Eucommiae water extract with concentration of 3 g/L.
Preparation of green olive juice: putting the cleaned green olive into boiling water, adding 0.1% citric acid solution, scalding for 5min, taking out, washing in flowing water to remove surface wax, softening pulp tissue, and protecting color; extracting the pitted olive pulp in a material-water ratio of 1:5(g/mL) for 2h at 50 ℃ and 400r/min in a temperature-controlled stirrer; filtering the extracted olive juice with gauze to obtain clear and transparent green olive juice.
The baking soda and the sodium bicarbonate have the molecular formula of NaHCO3Is an inorganic salt. Purchased from the market.
The L-carnitine disclosed by the invention is also called L-carnitine and vitamin BT, has a chemical formula of C7H15NO3, and is purchased from the market.
The monosodium glutamate is sodium glutamate, is a delicate flavor seasoning, and is easily soluble in water; purchased from the market.
Example 1
Step 1, adding 0.2g of baking soda into 99ml of alkaline ionized water, and uniformly stirring until the pH value reaches 12.5;
step 2, adding 0.1g of L-carnitine into the soda alkaline water obtained in the step 1, uniformly stirring, and standing;
step 3, adding 0.1g of eucommia bark water extract and 0.01g of green olive juice into the solution obtained in the step 2, and filtering;
step 4, heating the filtrate obtained in the step 3, adding 0.01g of monosodium glutamate, standing and filtering;
and 5, concentrating the liquid obtained in the step 4 to a relative density of 1.10-1.15 at 25 ℃, and filling the spray into a filling machine to obtain the cold compress spray.
Example 2
Step 1, adding 1.8 of baking soda into 97g of alkaline ionized water, and uniformly stirring until the pH value reaches 13;
step 2, adding 0.5g of L-carnitine into the soda alkaline water obtained in the step 1, uniformly stirring, and standing;
step 3, adding 0.5g of eucommia bark water extract and 0.1g of green olive juice into the solution obtained in the step 2, and filtering;
step 4, heating the filtrate obtained in the step 3, adding 0.1g of monosodium glutamate, standing and filtering;
and 5, concentrating the liquid obtained in the step 4 to a relative density of 1.10-1.15 at 25 ℃, and filling the spray into a filling machine to obtain the cold compress spray.
Example 3
Step 1, adding 1.0g of baking soda into 98g of alkaline ionized water, and uniformly stirring until the pH value reaches 12-13;
step 2, adding 0.2g of L-carnitine into the soda alkaline water obtained in the step 1, uniformly stirring, and standing;
step 3, adding 0.4g of eucommia bark water extract and 0.04g of green olive juice into the solution obtained in the step 2, and filtering;
step 4, heating the filtrate obtained in the step 3, adding 0.06g of monosodium glutamate, standing and filtering;
and 5, concentrating the liquid obtained in the step 4 to a relative density of 1.10-1.15 at 25 ℃, and filling the spray into a filling machine to obtain the cold compress spray.
Comparative example 1:
step 1, adding 1.0g of baking soda into 98g of deionized water, and uniformly stirring;
step 2, adding 0.2g of L-carnitine into the soda alkaline water obtained in the step 1, uniformly stirring, and standing;
step 3, adding 0.04g of green olive juice into the solution obtained in the step 2, and filtering;
step 4, heating the filtrate obtained in the step 3, adding 0.06g of monosodium glutamate, standing and filtering;
and 5, concentrating the liquid obtained in the step 4 to a relative density of 1.10-1.15 at 25 ℃, and filling the spray into a filling machine to obtain the cold compress spray. .
Comparative example 2
Step 1, adding 1.0g of baking soda into 98g of alkaline ionized water, and uniformly stirring until the pH value reaches 12-13;
step 2, adding 0.4g of eucommia bark water extract into the solution obtained in the step 1, and filtering;
step 3, heating the filtrate obtained in the step 2, adding 0.06g of monosodium glutamate, standing and filtering;
and 4, concentrating the liquid obtained in the step 3 to a relative density of 1.10-1.15 at 25 ℃, and filling the spray into a filling machine to obtain the cold compress spray.
The first experimental example: acute footpad swelling test of sodium urate crystal of spray rat
Preparing sodium urate crystal and sodium urate solution: adding 2g of uric acid into 400ml of boiling water, adjusting the pH value to 7.4 by using NaOH (1N), heating to 95 ℃, cooling at room temperature, stirring lightly, standing at 4 ℃ for 4-6 hours, separating out flocculent precipitate, filtering to obtain microcrystalline sodium urate, and sterilizing at 80 ℃. 1000mg of sodium urate is weighed before use, fully ground and added with 20ml of sterile physiological saline to prepare 50g/L (5%) of suspension.
Grouping and administration: rats were fed adaptively for 3 days, and were randomly divided into 5 groups by weight: model control group, positive drug indomethacin group (0.0045g/kg), experiment 1 group, experiment 2 group, and experiment 3 group. The indometacin group as the positive drug is administered by intragastric administration (10ml/kg) 1 hour before causing inflammation; the other groups were coated immediately after molding (0.1L/piece), and were re-coated 6, 12, and 24 hours after inflammation, and the model groups were coated with the same volume of vehicle.
Experiment 1 group sprays prepared in example 1 of the present invention.
Experiment 2 group sprays prepared in example 2 of the present invention.
Experiment 3 group sprays prepared in example 3 of the present invention.
Comparative example 1 group.
Comparative example 2 group.
Preparing a model: the circumference of the joint was measured as a normal value by a plantar volume measuring instrument. In each group, 0.2mL of 5% sodium urate suspension was injected into the dorsal aspect of the right ankle joint (joint extension, 45 degree needle insertion) of the rats for joint cavity molding.
Swelling degree of joints: the volume of the right ankle joint was measured 6, 12, 24, 48 hours after the onset of inflammation. And the swelling degree of the joint was calculated, and the results are shown in table 1.
Swelling degree is equal to the volume of the joint after molding-the volume of the joint before molding
Table 1 effect on sodium urate induced ankle swelling in rats (X ± SD, n ═ 9)
And (4) conclusion: modeling comparison group: after 6h, the ankle joint volume of the rat is obviously increased, swelling is gradually reduced along with the time, but the ankle joint does not return to normal after 48h, and the difference is significant compared with that before inflammation (P is less than 0.01). Compared with the model group, the experiment 1 group, the experiment 2 group and the experiment 3 group obviously reduce the ankle joint volume of the rat (P is less than 0.05 and P is less than 0.01); while the comparative example 1 and comparative example 2 did not improve ankle joint volume, and were not statistically significant compared to the model control group.
Experimental example II analgesic test of spray of the present invention
A hot plate method is adopted, a mouse with the weight of 20-24 g and a female are taken, a physio-physiological experiment multi-purpose instrument is used, the temperature is adjusted to be 55 +/-0.5 ℃, and the foot of the mouse licked is used as an index of pain. The pain threshold was determined once every 5min for 2 times before administration and the mean was taken. Selecting mice with pain threshold value of 10-30 seconds, stable reaction and no jumping for test, wherein each group comprises 10 mice and is randomly divided into the following groups:
matrix group, 70% ethanol solution is given;
experiment 1 group sprays prepared in example 1 of the present invention;
experiment 2 group spray prepared in example 2 of the present invention;
experiment 3 group sprays made in example 3 of the present invention.
Comparative example 1 group.
Comparative example 2 group.
Each group of the double-sided hind paw primers was 15. mu.l/body, 15 min/time X3 times. The pain threshold is re-measured 15min, 30 min and 60 min after the last application, and is measured twice at 5min intervals, and the average is taken as the pain threshold. The results are shown in Table 2.
TABLE 2 Effect of sprays of the invention on Hot plate pain threshold in mice
The results prove that: the local spraying agent can improve the pain threshold caused by mouse hot plate method; while the sprays of the comparative examples did not increase the pain threshold in mice, it is sufficient to show that the composition of the invention is not a simple combination but an organic combination in its entirety.
Claims (4)
1. A cold compress spray for relieving gout is characterized in that the spray comprises the following raw materials: alkaline ionized water, sodium bicarbonate, L-carnitine, eucommia bark water extract, green olive juice and monosodium glutamate.
3. the cold compress spray for relieving gout as claimed in claim 1, wherein the pH value of the alkaline ionized water is 10.0-10.9.
4. The cold compress spray for relieving gout as claimed in claim 1, wherein the preparation method of the spray comprises the following steps:
step 1, adding baking soda into alkaline ionized water, and after uniformly stirring, enabling the pH value to reach 12-13;
step 2, adding L-carnitine into the soda alkaline water obtained in the step 1, uniformly stirring, and standing;
step 3, adding the eucommia bark water extract and the green olive juice into the solution obtained in the step 2, and filtering;
step 4, heating the filtrate obtained in the step 3, adding monosodium glutamate, standing and filtering;
and 5, concentrating the liquid obtained in the step 4 to a relative density of 1.10-1.15 at 25 ℃, and filling the spray into a filling machine to obtain the cold compress spray.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111664767.0A CN114224935A (en) | 2021-12-31 | 2021-12-31 | Cold compress spray for relieving gout and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111664767.0A CN114224935A (en) | 2021-12-31 | 2021-12-31 | Cold compress spray for relieving gout and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114224935A true CN114224935A (en) | 2022-03-25 |
Family
ID=80745193
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111664767.0A Pending CN114224935A (en) | 2021-12-31 | 2021-12-31 | Cold compress spray for relieving gout and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114224935A (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104825554A (en) * | 2015-04-22 | 2015-08-12 | 广州暨南生物医药研究开发基地有限公司 | Gouty arthritis treatment spraying agent |
CN109700901A (en) * | 2019-01-16 | 2019-05-03 | 曲沃李时珍医药科技有限公司 | A kind of Medical-use cold compress gel and its preparation method and application improving gout |
-
2021
- 2021-12-31 CN CN202111664767.0A patent/CN114224935A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104825554A (en) * | 2015-04-22 | 2015-08-12 | 广州暨南生物医药研究开发基地有限公司 | Gouty arthritis treatment spraying agent |
CN109700901A (en) * | 2019-01-16 | 2019-05-03 | 曲沃李时珍医药科技有限公司 | A kind of Medical-use cold compress gel and its preparation method and application improving gout |
Non-Patent Citations (13)
Title |
---|
余瀛鳌等: "杜仲茶", 《这本书能让你摆脱痛风 长效降尿酸,除痛防复发》 * |
余瀛鳌等: "杜仲茶", 《这本书能让你摆脱痛风 长效降尿酸,除痛防复发》, 28 February 2019 (2019-02-28), pages 138 * |
佚名: "橄榄油+小苏打,外用缓解痛风", 《百度》 * |
佚名: "橄榄油+小苏打,外用缓解痛风", 《百度》, 2 April 2021 (2021-04-02) * |
张玎减肥: "生酮饮食如何降低尿酸?", 《百度》 * |
张玎减肥: "生酮饮食如何降低尿酸?", 《百度》, 18 December 2018 (2018-12-18), pages 3 * |
洪良: "连翘治失眠 樟脑酒消肿止痛 青橄榄治痛风", 《百度》 * |
洪良: "连翘治失眠 樟脑酒消肿止痛 青橄榄治痛风", 《百度》, 28 September 2018 (2018-09-28), pages 1 * |
灰辟教概: "痛风可以吃鸡精和味精吗 痛风可以吃生抽吗", 《百度》 * |
灰辟教概: "痛风可以吃鸡精和味精吗 痛风可以吃生抽吗", 《百度》, 19 September 2018 (2018-09-19), pages 1 * |
藤田纮一郎: "《水的神奇疗效》", 31 May 2007, pages: 84 * |
赵春华: "中西医结合治疗痛风性关节炎13例", 《四川中医》, vol. 21, no. 09, 15 September 2003 (2003-09-15), pages 29 - 30 * |
陈大舜等: "《最好的中医名著公开课 名师解读历代名医临床必读医论》", 湖南科学技术出版社, pages: 367 - 368 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPS5843996A (en) | Stable s-adenosylmethionine salts, manufacture and therapeutical composition containing them as active components | |
CN103961556A (en) | Dendrobium officinale oculentum for relieving asthenopia | |
CN104382005A (en) | Glucosamine chondroitin collagen tablet and preparation method thereof | |
WO2021062888A1 (en) | Complex composition with function of promoting bone and joint health and application thereof | |
CN114224935A (en) | Cold compress spray for relieving gout and preparation method thereof | |
CN100350921C (en) | Dermatosis eliminating medicine | |
CN109464512A (en) | It is a kind of for treating the external wash liquid and preparation method thereof of pig scabies | |
CN102335462A (en) | Nano iodine-chitosan cervical disease treating membrane agent and preparation method of membrane | |
CN1057934C (en) | Electuary benefitting for liver and preparation method thereof | |
CN102670881A (en) | Chinese medicinal composition for treating fracture and preparation method | |
CN107114775B (en) | Blood fat reducing compound based on swim bladder polypeptide of miichthys miiuy and preparation method thereof | |
CN102579558B (en) | Application of bauhinia championii total flavonoids in preparation of medicine for treating rheumatoid arthritis | |
CN100471507C (en) | Traditional Chinese medicine prepn. for treating osteoporosis | |
CN115414368B (en) | Pharmaceutical composition for treating traumatic injury and application thereof | |
CN1170562C (en) | Medicine for treating tinea | |
CN114053340B (en) | A Chinese medicinal composition for treating rheumatism, and its preparation method | |
CN107811907A (en) | A kind of body lotion for promoting subcutaneous fat to decompose | |
CN115054645B (en) | Traditional Chinese medicine composition for relieving eye fatigue and preparation method thereof | |
CN102697964B (en) | Medicine for treating male sexual dysfunction | |
CN108434299B (en) | Pharmaceutical composition for treating scapulohumeral periarthritis and preparation method and spray thereof | |
CN112999340A (en) | Nasal cavity flushing fluid and preparation method thereof | |
CN105640792B (en) | Dihydromyricetin is in beauty except the application in spot product | |
CN105412395A (en) | Traditional Chinese medicine composition for treating hyperostosis and preparation method thereof | |
CN112915185A (en) | Pharmaceutical composition and preparation method and application thereof | |
CN1143684C (en) | Medicine for treating hypertension and heart disease and its preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20220325 |
|
WD01 | Invention patent application deemed withdrawn after publication |